乙型肝炎病毒相关肝细胞癌背景肝脏中的C反应蛋白过表达是

StephenW

J Pathol Transl Med. 2018 Jul 27. doi: 10.4132/jptm.2018.07.14. [Epub ahead of print]
C-reactive Protein Overexpression in the Background Liver of Hepatitis B Virus-Associated Hepatocellular Carcinoma Is a Prognostic Biomarker.
Shin JH1, Yu E1, Kim EN1, Kim CJ1.
Author information

1
    Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Abstract
Background:

Chronic hepatitis B virus (HBV) infection is a leading cause of hepatocellular carcinoma (HCC). Peripheral blood C-reactive protein (CRP) concentration and CRP overexpression in HCC cells are proven to be prognostic markers for HCC, but the significance of CRP expression in nonneoplastic hepatocytes, which are the primary origin of CRP, has not been studied. This study was conducted to determine the clinicopathologic significance of CRP immunoreactivity in the background liver of HBV-associated HCC.
Materials and Methods:

CRP immunostaining was done on tissue microarrays of nonneoplastic liver tissues obtained from surgically resected, treatment-naive HBV-associated HCCs (n=156). The relationship between CRP immunoreactivity and other clinicopathologic parameters including cancer-specific survival was analyzed. CRP immunoreactivity was determined using a 4-tier grading system: grades 0, 1, 2, and 3.
Results:

CRP was positive in 139 of 156 cases (89.1%) of nonneoplastic liver in patients with HCCs: grade 1 in 83 cases (53.2%); grade 2 in 50 cases (32.1%); and grade 3 in 6 cases (3.8%). The patients with diffuse CRP immunoreactivity (grade 3) had decreased cancer-specific survival (P=.0031) and a tendency for shorter interval before early recurrence (P=.050). The degree of CRP immunoreactivity correlated with serum CRP concentration (P<.001).
Conclusion:

CRP immunoreactivity in nonneoplastic liver is a novel biomarker for poor cancer-specific survival of HBV-associated HCC and correlates with serum CRP concentration.
KEYWORDS:

C-reactive protein; Hepatitis B virus; Hepatocellular carcinoma; Immunohistochemistry; Prognosis

PMID:
    30056637
DOI:
    10.4132/jptm.2018.07.14

桦子

J Pathol Transl Med。 2018年7月27日doi：10.4132 / jptm.2018.07.14。 [提前打印]
乙型肝炎病毒相关肝细胞癌背景肝脏中的C反应蛋白过表达是预后的生物标志物。
Shin JH1，Yu E1，Kim EN1，Kim CJ1。
作者信息

1
     韩国首尔蔚山大学医学院牙山医学中心病理科

抽象
背景：

慢性乙型肝炎病毒（HBV）感染是肝细胞癌（HCC）的主要原因。 HCC细胞中外周血C反应蛋白（CRP）浓度和CRP过表达被证明是HCC的预后标志物，但CRP表达在非肿瘤性肝细胞（CRP的主要起源）中的重要性尚未得到研究。本研究旨在确定HBV相关HCC背景肝脏中CRP免疫反应性的临床病理学意义。
材料和方法：

在从手术切除的，未经治疗的HBV相关HCC获得的非肿瘤肝组织的组织微阵列上进行CRP免疫染色（n = 156）。分析了CRP免疫反应性与其他临床病理参数（包括癌症特异性存活）之间的关系。使用4级分级系统测定CRP免疫反应性：0,1,2和3级。
结果：

在HCC患者中，156例（89.1％）非肿瘤性肝脏中CRP阳性：83例（53.2％）为1级;二级50例（32.1％）;和3级6例（3.8％）。具有弥漫性CRP免疫反应性（3级）的患者具有降低的癌症特异性存活率（P = .0031）和早期复发前间隔较短的趋势（P = .050）。 CRP免疫反应程度与血清CRP浓度相关（P <.001）。
结论：

非肿瘤性肝脏中的CRP免疫反应性是HBV相关HCC的癌症特异性存活率差的新生物标志物，并且与血清CRP浓度相关。
关键词：

C反应蛋白;乙型肝炎病毒;肝细胞癌;免疫组化;预测

结论：
     30056637
DOI：
     10.4132 / jptm.2018.07.14